Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 15/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413569 | 0.87 | ADORA3 (0.45) | ADORA3ADORA1ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL19706738 | 0.81 | NPC1 (0.44) | ADORA3ADORA1ADORA2AADORA2BTSHR | |
| SCHEMBL19706555 | 0.80 | KDM4E (0.46) | ADORA3ADORA1ADORA2AADORA2BRAB9A | |
| SCHEMBL23368466 | 0.79 | ADORA3 (0.40) | ADORA3ADORA1ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL17778400 | 0.77 | ADORA3 (0.38) | ADORA3ADORA1ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL19151182 | 0.77 | ADORA3 (0.50) | ADORA3ADORA1ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL19699477 | 0.76 | FFAR2 (0.42) | ADORA3ADORA1ADORA2AADORA2BABL1 | |
| SCHEMBL30071274 | 0.76 | SMN1; SMN2 (0.51) | ADORA3ADORA1ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL17778558 | 0.73 | CHEK1 (0.40) | ADORA3ADORA1ADORA2AADORA2BABL1 | |
| SCHEMBL1722219 | 0.71 | RAB9A (0.55) | TSHRSMN1; SMN2NPC1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ADORA3 3318/4885ADORA1 2592/4885ADORA2A 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.